Drugs that contain Rotigotine
1. List of Neupro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(5 months from now) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(2 years from now) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(4 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(9 years from now) | |
Market Authorisation Date: 09 May, 2007
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
11
United States
9
European Union
6
China
5
Korea, Republic of
4
Japan
3
Brazil
3
Australia
3
Poland
3
Spain
3
Mexico
3
Slovenia
3
Portugal
3
Canada
3
Denmark
2
Austria
2
Hong Kong
2
Germany
2
Israel
2
South Africa
2
Norway
1
RS
1
Lithuania
1
Cyprus
1
Hungary
1
Croatia
1
EA
1
Turkey
1
ME
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic